Dr. Hari on CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma


Parameswaran Hari, MD, MRCP, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Data from the phase Ib/II CARTITUDE-1 trial (NCT03548207), which examined the efficacy of the anti-BCMA CAR T-cell therapy JNJ-68284528 (JNJ-4528) in 29 patients with heavily pretreated relapsed/refractory multiple myeloma, were presented at the 2019 ASH Annual Meeting.

All patients were triple-exposed, meaning that they received a CD38 monoclonal antibody, an immunomodulatory drug, and a proteasome inhibitor, says Hari, with 86% of patients identified as being triple-refractory. Treatment with the product led to an overall response rate of 100%. Specifically, the ORR was comprised of a 66% stringent complete response (CR) rate, a 3% CR rate, a 17% very good partial response (PR) rate, and a 14% PR rate.

It is unknown how long these responses will last or how much this treatment will eventually cost, but for a disease with extremely poor prognosis, BCMA targeting with CAR T-cells remains a wonderful opportunity for development, says Hari.

In fact, these products are expected to move forward into earlier lines of treatment and change the natural history of the disease, concludes Hari.

Related Videos
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
© 2024 MJH Life Sciences

All rights reserved.